Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06161571 · ClinicalTrials.gov registry record · Phase 3
A Study Evaluating Efruxifermin in Subjects With Non-invasively Diagnosed Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Nonalcoholic Fatty Liver Disease (NAFLD)/Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
A Phase 3 study of NASH/MASH and NAFLD/MASLD, sponsored by Akero Therapeutics.
- Active
- Registry status
- Phase 3
- Development phase
- 700
- Enrollment target
- 20
- Study locations
NCT06161571 is a Phase 3 study of NASH/MASH and NAFLD/MASLD that is active but no longer recruiting, run by Akero Therapeutics. The registered enrollment target is 700 participants. The trial reports 20 study locations across 4 states.
The verdict
NCT06161571, a Phase 3 study of NASH/MASH and NAFLD/MASLD, is active but no longer recruiting, sponsored by Akero Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 700 participants
- Enrollment target
- 20
- Study locations
Study Summary
The aim of this study is to assess the safety and tolerability of EFX compared to placebo in subjects with non-invasively diagnosed NASH/MASH and NAFLD/MASLD.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Efruxifermin
Study Locations (20)
California
- Akero Clinical Study Site - Chula Vista
- Akero Clinical Study Site - Coronado
- Akero Clinical Study Site - Cypress
- Akero Clinical Study Site - Inglewood
- Akero Clinical Study Site - La Mesa
- Akero Clinical Study Site - Lancaster
- Akero Clinical Study Site - Los Angeles
- Akero Clinical Study Site - Los Angeles
- Akero Clinical Study Site - Palm Springs
- Akero Clinical Study Site - San Diego
Arizona
- Akero Clinical Study Site - Chandler
- Akero Clinical Study Site - Flagstaff
- Akero Clinical Study Site - Peoria
- Akero Clinical Study Site - Tucson
- Akero Clinical Study Site - Tucson
Arkansas
- Akero Clinical Study Site - Conway
- Akero Clinical Study Site - Jonesboro
- Akero Clinical Study Site - Little Rock
- Akero Clinical Study Site - North Little Rock
Alabama
- Akero Clinical Study Site - Birmingham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 700 participants |
| Start Date | 2023-11-10 |
| Est. Completion | 2026-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06161571
The ClinicalTrials.gov registry entry for NCT06161571 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 700 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Akero Therapeutics, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with NASH/MASH appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06161571 reports 20 study locations spanning 4 distinct geographic areas - top geographies include California, Arizona, Arkansas.
Frequently Asked Questions
What is clinical trial NCT06161571 about?
NCT06161571 is a clinical study titled "A Study Evaluating Efruxifermin in Subjects With Non-invasively Diagnosed Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Nonalcoholic Fatty Liver Disease (NAFLD)/Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)". The aim of this study is to assess the safety and tolerability of EFX compared to placebo in subjects with non-invasively diagnosed NASH/MASH and NAFLD/MASLD.
What is the current status of trial NCT06161571?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 700 participants. The study started on 2023-11-10. Estimated completion is 2026-10.
What conditions does trial NCT06161571 study?
This clinical trial studies the following conditions: NASH/MASH, NAFLD/MASLD.
What interventions are being tested in trial NCT06161571?
The interventions under investigation include: Placebo (DRUG), Efruxifermin (DRUG).
Who is sponsoring clinical trial NCT06161571?
This trial is sponsored by Akero Therapeutics, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06161571 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.